COMMUNICATION STYLE: BALANCED (Grade 10-12 reading level) WRITING RULES: - Use medical terms but define them on...

Question asked:

COMMUNICATION STYLE: BALANCED (Grade 10-12 reading level) WRITING RULES: - Use medical terms but define them on first use: "metastasis (cancer spread)" - Include key statistics in plain language: "about 7 out of 10 patients respond" - Mix of bullet points and short paragraphs - Explain WHY something is recommended, not just what - Mention relevant trials by name but don't cite PMIDs - Be informative but not overwhelming - 3-4 key points per perspective FORMAT: • Lead with the bottom line recommendation • Support with 2-3 evidence points • Include "Ask Your Oncologist" questions • Note any important caveats simply PATIENT CASE CONTEXT (use these specifics in your response): - Cancer Type: Poorly differentiated adenocarcinoma (esophagus) - Stage: confirmed - Biomarkers: CK7, CDX2, p40, CK5/6, UNKNOWN - Current/Prior Treatments: Prilosec (omeprazole) 40 mg PO daily, Neoadjuvant therapy, Omeprazole 40mg daily, Soft diet, Robotic Ivor Lewis esophagectomy, FLOT chemotherapy, Durvalumab Five oncology perspectives have analyzed this cancer case: 1. Standard of Care (NCCN guidelines) 2. Emerging Evidence (clinical trials, cutting edge) 3. Molecular/Targeted (precision medicine) 4. Watch & Wait (conservative, de-escalation) 5. Whole Person (quality of life, integrative) Standard of Care: The diagnosis is NOT 'unknown' - the patient has a confirmed Stage III GE junction Siewert Type I adenocarcinoma (esophageal cancer extending to the gastric cardia). The endoscopy clearly shows a fungating mass at the gastroesophageal junction with biopsy-confirmed poorly differentiated adenocarcinoma. This is a complete diagnosis requiring no further diagnostic workup before proceeding with the planned neoadjuvant FLOT chemotherapy. Recommendation: The diagnosis is complete and correct. Proceed with the planned treatment pathway: neoadjuvant FLOT chemotherapy followed by surgical resection. The only remaining question is whether PET/CT staging has been completed to confirm no distant metastases, which is standard before starting neoadjuvant therapy per NCCN guidelines. Emerging Evidence: The diagnosis is NOT unknown - your records clearly show Stage III GE junction Siewert I adenocarcinoma (poorly differentiated). The pathology confirmed invasive adenocarcinoma at the gastroesophageal junction with specific biomarker patterns (CK7+, CDX2+). This is a well-established diagnosis that should guide your treatment planning. Recommendation: Request comprehensive molecular profiling (NGS panel testing for alterations beyond standard biomarkers) to identify potential clinical trial matches. Ask your oncologist: 1) Has my tumor been tested for SWI/SNF alterations, MSI status, or TMB? 2) Are there trials combining durvalumab with novel agents for my specific molecular profile? 3) What are the expected pathologic response rates with my current FLOT + durvalumab regimen? Sources: biomcp_trials, biomcp_articles Molecular/Targeted: The diagnosis of 'unknown' is incomplete and contradicts the existing [ID removed] The patient has a confirmed diagnosis of Stage III GE junction Siewert I adenocarcinoma (poorly differentiated esophageal adenocarcinoma) based on endoscopy findings showing a fungating mass at the gastroesophageal junction and tissue biopsies. From a molecular perspective, this patient urgently needs comprehensive genomic profiling to identify actionable mutations that could guide targeted therapy selection. Recommendation: The diagnosis should be corrected to 'Stage III GE Junction Siewert I Adenocarcinoma (Poorly Differentiated)' based on existing pathology. Before starting the planned FLOT chemotherapy and durvalumab, request comprehensive molecular testing: (1) HER2 IHC/FISH testing, (2) PD-L1 expression (CPS score), (3) MSI/MMR status, and (4) comprehensive genomic profiling (NGS panel like Foundation One CDx or Tempus xT) to identify any actionable mutations that could add targeted therapies to the treatment plan or change the approach entirely. Watch & Wait: The diagnosis is NOT 'unknown' - your records clearly show esophageal adenocarcinoma at the gastroesophageal (GE) junction. However, critical staging information is incomplete. Before committing to aggressive neoadjuvant therapy and surgery, you need complete staging (CT chest/abdomen/pelvis, PET scan, and endoscopic ultrasound) to confirm this is truly localized disease and not metastatic, which would completely change the treatment approach from curative to palliative. Recommendation: Demand complete staging workup (CT, PET, EUS) BEFORE starting any treatment. If staging confirms truly localized Stage II-III disease, then neoadjuvant therapy makes sense. However, if occult metastases are found, you can avoid unnecessary surgery and focus on systemic therapy that preserves quality of life. Also request molecular testing (HER2, PD-L1, MSI) on your biopsy - these biomarkers may open additional treatment options and should be known upfront. Whole Person: The diagnosis is NOT 'unknown' - the patient has a confirmed diagnosis of Stage III GE junction Siewert I adenocarcinoma (poorly differentiated) based on endoscopy findings and pathology. From a Whole Person perspective, the diagnosis is complete enough to begin supportive care planning, but confirming the exact stage through PET/CT imaging is critical because it determines whether curative surgery is possible and helps set realistic expectations for treatment intensity and duration. Recommendation: The diagnosis itself is confirmed and correct - this is esophageal adenocarcinoma, not 'unknown.' However, complete staging with PET/CT scan should be confirmed before starting FLOT chemotherapy. Equally Synthesize ALL FIVE perspectives. You MUST respond with ONLY a valid JSON object (no markdown, no explanation before or after). Format: { "headline": "One sentence summarizing the most important takeaway", "synthesis": "2-3 sentences explaining the key findings in accessible language", "consensus": ["Point where most/all perspectives agree"], "divergence": ["Key disagreement between perspectives"], "decision_leverage": { "changes_management": ["What actually changes your treatment plan"], "vs_noise": ["Information that's good to know but doesn't require action"] }, "questions_for_team": ["1. Question to ask your oncologist about treatment options?", "2. Question about testing or monitoring?"], "monitoring_summary": "How success or failure will be measured" } CRITICAL FRAMING - DECISION LEVERAGE: You MUST distinguish between: - "changes_management": Recommendations that ACTUALLY CHANGE what the patient does (therapy selection, testing that guides therapy, monitoring that triggers decisions) - "vs_noise": Information that is true/interesting but doesn't change management (nice-to-know context, tests without treatment implications, generic advice) This distinction is the most valuable output. Patients need to know what to ACT on vs what to simply understand. QUESTIONS FOR TEAM: Generate 2-5 numbered questions the patient should ask their oncology team. These should be: - Specific to THIS case (not generic) - Actionable (can be answered with a decision or plan) - Prioritized (most important first) Example good questions: - "Given my BRCA2 status, should we discuss PARP inhibitor maintenance?" - "What objective criteria would indicate treatment failure?" - "Is there a clinical trial I'm eligible for based on my biomarkers?" Example bad questions (avoid): - "What are my options?" (too vague) - "Should I get a second opinion?" (generic) MONITORING SUMMARY: Explain HOW success or failure will be measured. Include: - What tests track response - What thresholds indicate success vs progression - How often monitoring should occur - The "headline" field is the most important - make it actionable and clear - Be specific about which perspectives agree or disagree - Focus on what the patient should discuss with their oncologist